The IBD pipeline: what's coming, and when

Oct 9

Biosimilars bought the headroom. This is what fills it.

3 Comments

Thomas Pilkington

Do you see any role for biosimilars in management of UC-PSC?

Charlie, at what point do you offer clinical trials to patients? With so many options its tempting to cycle through the classes when one is not efficacious but at what point do you steer towards a trial?

Grazie per queste tante buone notizie.

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts